Gender |
Female |
16 (40 %) |
|
Male |
24 (60 %) |
Age (years) |
Median (range) |
67 (53–81) |
|
RUL |
15 (37.5%) |
|
RML |
3 (7.5%) |
Tumour location* |
RLL |
7 (17.5%) |
|
LUL |
8 (20%) |
|
LLL |
8 (20%) |
Central (C)/ |
C |
17 (42.5%) |
peripheral (P) tumour location** |
P |
22 (55%) |
Histology |
NSCLC |
31 (77.5%) |
|
SCLC |
9 (22.5%) |
|
De novo lung cancer |
32 (80%) |
|
Local progression |
1 (2.5%) |
Disease treated |
Local recurrence reirradiation |
2 (5%) |
|
Regional recurrence |
1 (2.5%) |
|
Locoregional recurrence reirradiation |
4 (10%) |
|
Concurrent chemotherapy |
13 (32.5%) |
Systemic treatment |
Sequential chemotherapy |
16 (40%) |
|
Target therapy |
1 (2.5%) |
|
None |
10 (25%) |
|
T0 |
1 (2.5%) |
|
T1 |
4 (10%) |
Tumour (T) stage |
T2 |
14 (35%) |
|
T3 |
8 (20%) |
|
T4 |
13 (32.5%) |
|
N0 |
9 (22.5%) |
Lymph nodes (N) |
N1 |
1 (2.5%) |
stage |
N2 |
14 (35%) |
|
N3 |
16 (40%) |
Fractionation |
Conventional |
37 (92.5%) |
|
Hypofractionation |
3 (7.5%) |
Radiation technique |
VMAT |
40 (100%) |